RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06404099
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: All sites listed under NCT06404086, Durham, North Carolina
Conditions: Long COVID, Long COVID-19, Hypersomnia
Register for Updates
A Study of LY4060874 in Healthy Participants
NCT06709820
Recruiting
The purpose of this study is to evaluate safety and tolerability of LY4060874 in healthy participants. Study participation may last up to 22 weeks and up to approximately 16 study visits.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Fortrea, Inc., Dallas, Texas +1 locations
Conditions: Healthy Participants
Register for Updates
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Pediatric High-grade Glioma (HGG)
NCT06946680
Recruiting
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ pediatric high-grade glioma
Gender:
ALL
Ages:
Between 4 years and 18 years
Trial Updated:
04/18/2025
Locations: University of Florida Health Children's Hospital, Gainesville, Florida
Conditions: High-grade Glioma
Register for Updates
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
NCT00001595
Recruiting
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present study serves as a (i) screening/training, and, (ii) a research protocol. As a screening and traini... Read More
Gender:
ALL
Ages:
Between 3 years and 70 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
Register for Updates
Study of Endocrine-Related Conditions and Physiology
NCT03867448
Recruiting
Background: Endocrine disorders involve changes to glands that produce hormones. Hormones are released by these glands into the blood so they can direct the function of other tissues in the body. Researchers want to study people who may have endocrine disorders. They want to learn more about the conditions that affect endocrine glands. Objective: To study adults with a variety of endocrine disorders for research and physician education. Eligibility: Adults ages 18 and older who have an endo... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endocrine Disease
Register for Updates
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
NCT04897321
Recruiting
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive so... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
04/18/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Alabama Oncology, Birmingham, Alabama +190 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Combined Electric and Acoustic Hearing (EAS) in Children and Adults
NCT05923203
Recruiting
Cochlear implants are surgically implanted devices which restore the ability to hear to the hearing impaired. Improvements in surgery and electrodes have results in an increased number of adults and children who have residual hearing and can benefit from electric and acoustic hearing in the same ear. This is called Electric Acoustic Stimulation (EAS). Many studies have shown that adult EAS users show significant benefits for speech understanding in noise and spatial hearing tasks as compared to... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
04/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee +2 locations
Conditions: Cochlear Implant, Hearing Loss
Register for Updates
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT06253494
Recruiting
Background: Endometrial cancer (EC) of the uterus is becoming more common in the US. Sometimes EC often has increased levels of a protein called HER2. Cancers with HER2 tend to be more aggressive and have poorer outcomes. Objective: To test 2 study drugs-a vaccine that targets HER2 (AdHER2DC) plus a drug that supercharges immune cells that kill tumor cells (N-803)-combined with 2 FDA-approved cancer treatment drugs in people with EC. Eligibility: Adults aged 18 and older with HER2-positive... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Register for Updates
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NCT06404112
Recruiting
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices. This platform protocol is a prospect... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: All sites listed under NCT06404086, Durham, North Carolina
Conditions: Long COVID, Long COVID-19, Sleep Disturbance
Register for Updates
Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds
NCT06750809
Recruiting
The goal of this study is to compare the cost and clinical outcomes for two temporary dressings (Allograft and PermeaDerm) used in patients that need a skin graft to heal their wound. The researchers will review cost and other treatment results including how well both temporary dressings attach to the skin, how prepared the wound bed is to receive a skin graft, how long it takes for the skin to be ready to receive a skin graft, how well the skin graft takes and any complications. Patients will f... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/18/2025
Locations: Valleywise Health, Phoenix, Arizona +3 locations
Conditions: Surgical Wound, Trauma Wound, Autografts, Partial Thickness Wounds, Partial-thickness Burn
Register for Updates
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
NCT00242723
Recruiting
Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein. * Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in patients. * A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them. Objectives: * To evaluate people wi... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, Lung Cancer NOS, Thoracic Cancers, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura
Register for Updates